Term
Mixed a1 & a2
Adrenergic receptor antagonists
Drugs |
|
Definition
- Phenoxybenzamine
- Covalently binds a receptors
- Irreversible antagonist of a1 and a2 receptors
- Phentolamine
- Competetive, reversible antagonist of a1 and a2 receptors
|
|
|
Term
Mixed a1 and a2
Adrenergic receptor antagonist
Physiological effects
(5) |
|
Definition
- Vascular
- Blockade of a1 and a2 adrenergic receptors leads to;
- vasodilation
- decreased peripheral resistance
- decrease BP
- Cardiac
- Can indirectly increase heart rate (reflex tachycardia)
|
|
|
Term
Mixed a1 and a2
Adrenergic receptor antagonist
Therapeutic uses
(4) |
|
Definition
- Pheochromocytoma
- Short-term pre- and- peri operative management (Phentolamine)
- Long-term management of pts who are not surgical candidates (Phenoxybenzamine)
- Manage local ischemic necrosis (Phentolamine)
|
|
|
Term
Mixed a1 and a2
Adrenergic receptor Antagonist
Adverse Effects
(3) |
|
Definition
- Orthostatic hypotension with reflex tachycardia and arrhythmias
- nasal stuffiness
- GI irritation, N/V
|
|
|
Term
Mixed a1 and a2
Adrenergic receptor Antagonist
Contraindications/Precautions
(4) |
|
Definition
- Patients with coronary artery disease (e.g. MI, atherosclerosis)
- Administration of mixed sympathomimetic drugs (e.g. Epi)
- Precaution because B receptor activation will be unopposed (a receptors blocked), which can lead to profound hypotensive episode with reflex tachycardia
|
|
|
Term
Selective a1
Adrenergic receptor Antagonists
The drugs
(5) |
|
Definition
- Doxazosin
- Terazosin
- Prazosin
- Tamsulosin
- Selective a1a receptors
- Alfazosin, silodosin also selective for a1a receptors
- Hint, all end with "sin"
|
|
|
Term
Selective a1
Adrenergic receptor Antagonists
Physiological Effects
(5) |
|
Definition
NOTE: a1a selective antagonists have less effect on cardiovascular system and thus are not indicated for management of hypertension
- Vascular
- Vasodilation-due to a1 receptor blockade => dec. TPR => dec. BP
- Cardiac
- Less change than w/ non-selective a antagonists
- Genitourinary
- Relaxation of smooth muscle in bladder base and neck, as well as of prostate and its capsule
- Decreased resistance to urine outflow (Decreases "dynamic component" of bladder outflow obstruction)
|
|
|
Term
Selective a1
Adrenergic receptor Antagonists
Therapeutic Uses
(6) |
|
Definition
- Primary systemic hypertension
- Doxazosin, Terazosin, & Parazosin are the only a antagonists used to treat mild to moderate systemic hypertension
- That is Tamsulosin, alfazosin, & Silodosin are not used for HTN b/c are selective for a1a receptors in prostate/bladder
- Benign Prostatic Hypertrophy (BPH)
- AKA "Lower urinary tract symptoms" or LUTS
- All currently available a1 antagonists except for prazosin have this indication (prazosin is not indicated for BPH b/c it requires dosing of 2-3Xa day, others are all 1/day
|
|
|
Term
Selective a1
Adrenergic receptor Antagonists
Adverse Effects
(6) |
|
Definition
- Syncope & "1st dose phenomenon"
- Postural hypotension & dizziness or syncope may be experienced on 1st dose.
- Not as likely with a1a selective antagonists, but can still be seen
- Drowsiness &/or asthma (fatigue, weakness)
- Nasal congestion/rhinitis
- Retrograde ejaculation (Particularly for a1a selective antagonists)
|
|
|
Term
Selective a1
Adrenergic receptor Antagonists
Contraindications/Precautions
(1) |
|
Definition
- Warn patients about 1st dose phenomenon
|
|
|
Term
B Receptor Antagonists
The drugs
(7) |
|
Definition
- Non-selective B antagonists; Affinity for B1=B2
- Propranolol: increases survival in pts w/ MI
- Nadolol: t1/2 in plasma is 20 hrs. Unique in long duration of action
- Timolol: 1st FDA approved drug for topical treatment of glaucoma. Also shown to improve survival in pts with ischemic heart disorder
- B1 Selective antagonists
- Metoprolol: reduces mortality in MI and CHF
- Atenolol: Reduces vascular mortality rate in acute MI
- Esmolol: Unique in its short duration of action, t1/2=8 mins. For perioperative, itra operative, and emergency management of tachycardia &/or hypertension
- Betazolol: Only B1 slective antagonist available for treatment of glaucoma
- Hint; end in "olol"
|
|
|
Term
B Receptor Antagonists
Physiological Effects
Heart
(4) |
|
Definition
- Decrease HR & cardiac contractility (due to blockade of B1 receptors in the heart
- Normally, B blockade will impair exercise tolerance, b/c they will block the increase in cardiac output needed to exercise well
- However, in pts w/ angina pectoralis, exercise tolerance may be improved b/c the exercise tolerance in such pts is often limited by the development of anginal pain (due to cardiac workload exceeding available blood supply to the heart)
- By limiting exercise-induced increase in cardiac workload, B blockers may allow such pts to exercise longer
|
|
|
Term
B Receptor Antagonists
Physiological Effects
Vascular, Renal, Respiratory
(3) |
|
Definition
- Vascular
- There is a central effect of B adrenergic receptor blockade that leads to decreased sympathetic outflow, & therefore, decreased peripheral resistance.
- Renal
- Decreased renin release from juxtaglomerular cells (B1 receptor)
- Respiratory
- Life-threatening bronchial constriction in pts w/ asthma or other forms of COPD (B2 receptor)
|
|
|
Term
B Receptor Antagonists
Physiological Effects
Metabolic, Aqueous Humor, Other
(5) |
|
Definition
- Metabolic
- Decrease glycogenolysis and glucose mobilization in response to hypoglycemia (B2 receptors)
- Aqueous humor
- Decreased production of aqueous humor by ciliary body (B1 & 2 receptor)
- Other
- Note that propranolol and to a lesser extent, betaxolol & alebutolol have membrane-stabilizing activity independent of B receptor blockade
- This property likely underlies/contributes to some of the therapeutic benefit of these agents
|
|
|
Term
B Receptor Antagonists
Therapeutic Uses
(9) |
|
Definition
- Primary systemic hypertension (all except esmolol, sotalol)
- Congestive heart failure (Metoprolol)
- Acute MI/Prevention of recurrent MI (Propranolol, Timolol, Metoprolol, Atenolol)
- Angina pectoralis (Nadolol, Propranolol, Atenolol, Metoprolol)
- Cardiac arrhythmias (Propranolol, Esmolol, Sotalol, Acebutolol)
- Open-angle glaucoma (Timolol, Betaxolol, Cartelol, Levobunolol, Metipranolol)
- Pheochromocytoma (Propranolol after a blockade is in place)
- Migrane prophylaxis (Propranolol, Timolol)
- Essential Tremor (Propranolol)
|
|
|
Term
B Receptor Antagonists
Adverse Effects
(6) |
|
Definition
- Bradycardia
- Bronchial constriction
- Disrupted glucose balance
- Black box warning
- Atenolol, metoprolol, nadolol, propranolol, timolol
- Exacerbation of angina, MI, & ventricular arrhythmias if discontinued abruptly
- Need to taper down
|
|
|
Term
B Receptor Antagonists
Contraindications/Precautions
(6) |
|
Definition
- Pts w/ greater than 1st degree AV block
- Pts w/ sinus bradycardia
- Pts w/ cardiogenic shock/overt cardiac failure
- Use in caution in pts w/
- Diabetes (particularly non-selective B receptor antagonists)
- Compensated congestive heart failure
- Thyrotoxicosis (may mask signs of developing of progressing hyperthyroidism)
- Bronchospastic disorders (non-selective B receptor antagonists are contraindicated in such pts)
|
|
|
Term
Mixed a1-B antagonists
Drugs
|
|
Definition
|
|
Term
Mixed a1-B antagonists
Pharmacology and Physiological Effect
|
|
Definition
- Pharmacology
- Non-selective is blockade
- a1 blockade
- anti-oxidant effects (preclinical models)
- nitric oxide production (Carvedilol)
- Physiological Effects
- as listed previously for a and B receptor antagonists
|
|
|
Term
Mixed a1-B antagonists
Therapeutic Uses
|
|
Definition
- Treatment of hypertension (as for B blockers)
- Treatment of congestive heart failure
- B-block:
- Decreases HR & contractility, thereby decreasing cardiac workload.
- Decreases likelihood of fetal arrhythmia
- Decreases detrimental effects of excessive catecholamines on myocardial cells
- a1-Block/Possible NO production
- Decrease TPR, leading to decreased afterload & preload
|
|
|
Term
Mixed a1-B antagonists
Adverse Effects
Contraindications/Precautions |
|
Definition
- Adverse effects
- Bradycardia
- hypotension
- dizziness
- Contraindication/Precautions
|
|
|
Term
|
Definition
- Clonidine
- Guanfacine (used in mngmt of ADHD as well)
- Guanabenz
- Methyldopa
- Produces a-methyl norepinephrine, which then acts on a2 receptors in the brain to decrease sympathetic outflow
|
|
|
Term
a2 Agonists
Physiological Effects
(3)
|
|
Definition
- Initial hypertensive response (due to direct stimulation of a2 receptors on VSM) followed shortly thereafter by prolonged hypotensive response due to decreased Norepinephrine
- Stimulation of a2 receptors in the brainstem decreases sympathetic outflow and increases vagal tone (parasympathetic)
- Stimulation of a2 receptors on terminals of nerves decreasaes norepinephrine release, thereby also decreasing sympathetic tone.
|
|
|
Term
a2 Agonists
Therapeutic Uses, Adverse Effects,
Contraindications/Precautions
(6) |
|
Definition
- Therapeutic uses
- Treatment of hypertension
- Adverse effects
- Dry mouth
- Drowsiness/sedation
- Hypotension/dizziness
- Contraindications/precautions
- Withdrawal slowly to prevent severe rebound HTN
- Use w/ caution in pts taking other drugs that affect sinus node funtion or AV nodal conduction and in pts w/ coronary insufficiancy or cerebral vascular disease
|
|
|
Term
Drugs that Deplete Norepinephrine Stores
(1) |
|
Definition
|
|
Term
Reserpine
Pharmacological Effects
(7) |
|
Definition
- Pharmacological effects
- Binds to transporter on storage vesicles
- Prevents the storage of catecholamines
- Decreased;
- Cardiac output
- Peripheral resistance
- Renin release
- Na+ and H2O retention
|
|
|
Term
Reserpine
Therapeutic Uses
|
|
Definition
- Treatment of hypertension
- Relief of symptoms in agitated psychotic states
|
|
|
Term
Reserpine
Adverse Effects
(2) |
|
Definition
- Sedation and inability to concentrate are most common
- Depression- uncommon but serious
|
|
|
Term
Reserpine
Contraindications/Precautions
(5) |
|
Definition
- Contraindicated in pts with;
- depression or a history of depression
- Or receiving electroconvulsive therapy
- Contraindicated in pts with active peptic ulcer or ulcerative colitis.
- Use with caution in pts with a history of diseases (Resperine increases gastric acid secretion and GI motility)
- Receptor supersensitivity (Patient will experience exaggerated response to direct-acting sympathomimetic drugs)
|
|
|